Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Southern California
With
PRIMARY OBJECTIVE: I. To assess the pathological partial response (PPR) rate in patients with potentially resectable cutaneous squamous cell carcinoma (CSCC) treated with neoadjuvant cemiplimab. SECONDARY OBJECTIVES: I. To estimate the pathological complete response rate (PCR). II. To estimate the Response Evaluation Criteria in Solid Tumors (RECIST) (version \[v\]1.1) 9 week objective response rate (ORR). III. To estimate the RECIST (v1.1) 12 month progression free (PFS). IV. To assess the toxicity among patients with CSCC treated with neoadjuvant cemiplimab. EXPLORATORY OBJECTIVES: I. To evaluate tumor mutational burden (TMB) and correlate with response to PD-1 blockade therapy. II. To evaluate PD-L1 expression on CSCC tumor cells and correlate with response to PD-1 blockade. III. To evaluate CD8+ T cell infiltration into CSCC tumors and correlate with response to PD-1 blockade. IV. To assess other adaptive immune resistance mechanisms in CSCC tumors. OUTLINE: Patients receive cemiplimab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles (or up to 4 cycles for patients whose disease is unresectable after 3 cycles) in the absence of disease progression or unacceptable toxicity. Within 6 weeks of last dose of therapy, patients with potentially resectable tumors undergo surgical resection. After completion of study treatment, patients are followed up every 3 months for 24 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
